发明名称 |
PROBIOTIC GRAM-POSITIVE BACTERIA FOR THE PROPHYLAXIS, SUPPRESSION, OR ELIMINATION OF ALLERGIC REACTIONS IN HUMAN |
摘要 |
A method for a prophylaxis, suppression or elimination of an allergic reaction in a human, or for shifting the TH1-TH2 balance in a human body toward an increase of TH1 or a decrease of TH2 or both an increase in TH1 and a decrease in TH2, includes the steps of preparing a pharmaceutical composition having genomic DNA of at least one probiotic, gram-positive bacteria strain selected from the group Lactobacillus gasseri PA 16/8, Bifidobacterium bifidum MF 20/5, Bifidobacterium bifidum MG 20/5, Bifidumbacterium longum SP 07/3, Lactobacillus rhamnosus GG (92164) or a combination thereof, as an active ingredient, the at least one probiotic, gram-positive bacteria strain being present in the form of at least one of viable bacteria and inactivated bacteria, and administering to a human as suppository, vaginally, as a cream applied to skin, rectally, as a subcutaneous injection, as intravenous injection, as an inhalation liquid, or orally in combination with food. |
申请公布号 |
US2014288159(A1) |
申请公布日期 |
2014.09.25 |
申请号 |
US201314089502 |
申请日期 |
2013.11.25 |
申请人 |
Schrezenmeir Jürgen |
发明人 |
Schrezenmeir Jürgen |
分类号 |
C12N15/11 |
主分类号 |
C12N15/11 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for a prophylaxis, suppression or elimination of an allergic reaction in a human, or for shifting the TH1-TH2 balance in a human body toward an increase of TH1 or a decrease of TH2 or both an increase in TH1 and a decrease in TH2, comprising the steps of:
preparing a pharmaceutical composition comprising:
genomic DNA of at least one probiotic, gram-positive bacteria strain selected from the group consisting of Lactobacillus gasseri PA 16/8, Bifidobacterium bifidum MF 20/5, Bifidobacterium bifidum MG 20/5, Bifidumbacterium longum SP 07/3, Lactobacillus rhamnosus GG (92164) and a combination thereof, as an active ingredient in said pharmaceutical composition, said at least one probiotic, gram-positive bacteria strain being present in the form of at least one of viable bacteria and inactivated bacteria; and, administering said pharmaceutical composition to a human via a suppository, vaginally, via a cream applied to skin, rectally, via a subcutaneous injection, via intravenous injection, via inhalation liquid and a combination thereof. |
地址 |
Karlsruhe DE |